Predictors for Fibrosis Regression in Chronic HCV Patients after the Treatment with DAAS : Results of a Real-world Cohort Study
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
INTRODUCTION: The goal of treatment of chronic hepatitis C (HCV) is viral eradication. However, obtaining histological regression is even more important, because it will reduce the overall morbidity and mortality related to cirrhosis. Introduction of direct-acting antivirals (DAAs) in HCV improves rates of sustained virologic response (SVR). However, fibrosis regression has not been extensively assessed. The aim of this study was to detect the factors affecting fibrosis regression in chronic HCV patients treated with interferon containing regimens versus interferon-free DAA regimens.
METHODS: This prospective observational cohort study was conducted at the Tropical Medicine and Infectious Diseases Department, Tanta University, Egypt, between October 2015 and December 2017. Transient elastography (FibroScan®) examination was performed before therapy, at SVR12, 6 months and 1 year after completing therapy for cured patients.
RESULTS: Reduction in fibrosis was reported in; 46.7% and 49.3% of patients with moderate fibrosis, and 89% and 78.7% of patients with advanced fibrosis after one year of interferon containing and interferon free DAAs regimens respectively. Using multiple regression analysis; it was found that BMI, degrees of hepatic stiffness and steatosis were related to regression of hepatic fibrosis after therapy.
CONCLUSION: DAAs with or without interferon resulted in a significant reduction of liver fibrosis. BMI, steatosis and liver stiffness were independent factors for fibrosis regression in chronic HCV patients treated with DAAs. Further studies are needed to explore the mechanism by which steatosis affects HCV related fibrosis regression after treatment with DAAs.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Endocrine, metabolic & immune disorders drug targets - 20(2020), 1 vom: 26., Seite 104-111 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Soliman, Hanan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9008-11-1 |
|---|
| Anmerkungen: |
Date Completed 24.11.2020 Date Revised 24.11.2020 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1871530319666190826150344 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM300583869 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM300583869 | ||
| 003 | DE-627 | ||
| 005 | 20231225102830.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1871530319666190826150344 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1001.xml |
| 035 | |a (DE-627)NLM300583869 | ||
| 035 | |a (NLM)31448717 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Soliman, Hanan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Predictors for Fibrosis Regression in Chronic HCV Patients after the Treatment with DAAS |b Results of a Real-world Cohort Study |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.11.2020 | ||
| 500 | |a Date Revised 24.11.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a INTRODUCTION: The goal of treatment of chronic hepatitis C (HCV) is viral eradication. However, obtaining histological regression is even more important, because it will reduce the overall morbidity and mortality related to cirrhosis. Introduction of direct-acting antivirals (DAAs) in HCV improves rates of sustained virologic response (SVR). However, fibrosis regression has not been extensively assessed. The aim of this study was to detect the factors affecting fibrosis regression in chronic HCV patients treated with interferon containing regimens versus interferon-free DAA regimens | ||
| 520 | |a METHODS: This prospective observational cohort study was conducted at the Tropical Medicine and Infectious Diseases Department, Tanta University, Egypt, between October 2015 and December 2017. Transient elastography (FibroScan®) examination was performed before therapy, at SVR12, 6 months and 1 year after completing therapy for cured patients | ||
| 520 | |a RESULTS: Reduction in fibrosis was reported in; 46.7% and 49.3% of patients with moderate fibrosis, and 89% and 78.7% of patients with advanced fibrosis after one year of interferon containing and interferon free DAAs regimens respectively. Using multiple regression analysis; it was found that BMI, degrees of hepatic stiffness and steatosis were related to regression of hepatic fibrosis after therapy | ||
| 520 | |a CONCLUSION: DAAs with or without interferon resulted in a significant reduction of liver fibrosis. BMI, steatosis and liver stiffness were independent factors for fibrosis regression in chronic HCV patients treated with DAAs. Further studies are needed to explore the mechanism by which steatosis affects HCV related fibrosis regression after treatment with DAAs | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Hepatitis C virus | |
| 650 | 4 | |a cirrhosis | |
| 650 | 4 | |a direct-acting antivirals | |
| 650 | 4 | |a fibrosis | |
| 650 | 4 | |a steatosis | |
| 650 | 4 | |a transient elastography. | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Interferons |2 NLM | |
| 650 | 7 | |a 9008-11-1 |2 NLM | |
| 700 | 1 | |a Ziada, Dina |e verfasserin |4 aut | |
| 700 | 1 | |a Salama, Marwa |e verfasserin |4 aut | |
| 700 | 1 | |a Hamisa, Manal |e verfasserin |4 aut | |
| 700 | 1 | |a Badawi, Rehab |e verfasserin |4 aut | |
| 700 | 1 | |a Hawash, Nehad |e verfasserin |4 aut | |
| 700 | 1 | |a Selim, Amal |e verfasserin |4 aut | |
| 700 | 1 | |a Abd-Elsalam, Sherief |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Endocrine, metabolic & immune disorders drug targets |d 2006 |g 20(2020), 1 vom: 26., Seite 104-111 |w (DE-627)NLM161976174 |x 2212-3873 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2020 |g number:1 |g day:26 |g pages:104-111 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1871530319666190826150344 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2020 |e 1 |b 26 |h 104-111 | ||